Psychedelics policy came sharply into focus in 2023, with advocates chalking multiple wins as the drug policy reform movement’s momentum continued to expand beyond marijuana at the local, state and federal levels.
It was a year defined by firsts: historic federal legislation signed into law mandating psychedelics clinical trials, first-ever Food and Drug Administration (FDA) guidance on conducting research using entheogenic substances, a novel congressional hearing, psilocybin services opening in Oregon and a new opportunity to legalize MDMA as a prescribed medicine, to name a few examples.
What started as a local decriminalization project has quickly become one of the most significant and fast-moving sectors of the modern-day drug policy reform movement. And notably, it’s a renaissance that’s increasingly being shaped under a bipartisan framework, with Republicans frequently leading on the issue in Congress and state legislatures across the country.
For advocates, 2023 did see certain setbacks, such as California’s governor vetoing a psychedelics legalization bill that narrowly advanced through the legislature. But by and large, the year saw the reform coalition expand and mature, gaining steam that activists plan to leverage in the New Year.
Here are the top psychedelics moments of 2023:
Biden signs defense bill that requires
Read full article on Marijuana Moment
